This study is exploring if a low dose of Buprenorphine (Belbuca) can help improve social motivation in people with schizophrenia. Social motivation is the drive to take part in social activities, and many people with schizophrenia experience a reduced desire to seek positive social interactions and a heightened drive to avoid negative ones. Currently, there are no medications specifically for this. This study will compare Buprenorphine to a placebo (an inactive substance) to see if it affects attention bias (how you focus on certain things) 90 minutes after taking the drug. You may be able to join if you are 18-60 years old, understand spoken English, have a diagnosis of schizophrenia, and have low social motivation. The study plans to enroll 40 participants, but its current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, attention bias, is measured 90 minutes after drug administration. Further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.